Biohaven Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Biohaven Ltd. (BHVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 181.32 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-10
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 141.65K shares, a 123.69% increase year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 39.67K shares, a 123.85% increase year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 93.20K shares, a 13.80% increase year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 23.53K shares, a 64.22% decline year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 197.77K shares, a 6.13% increase from fiscal 2024.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 186.34K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 141.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 181.32K shares 10-Q · filed 2026-08-10 | 274.52K shares derived: sum of 3 quarters · filed 2026-08-10 | 298.05K shares derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | 39.67K shares 10-Q · filed 2026-05-04 | 132.87K shares derived: sum of 2 quarters · filed 2026-05-04 | 156.40K shares derived: sum of 3 quarters · filed 2026-05-04 | 219.72K shares derived: sum of 4 quarters · filed 2026-05-04 | |
| 2025-12-31 | 93.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 116.73K shares derived: sum of 2 quarters · filed 2026-03-02 | 180.05K shares derived: sum of 3 quarters · filed 2026-03-02 | 197.77K shares 10-K · filed 2026-03-02 | |
| 2025-09-30 | 23.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 86.85K shares derived: sum of 2 quarters · filed 2025-11-10 | 104.57K shares 10-Q · filed 2025-11-10 | 186.47K shares derived: sum of 4 quarters · filed 2025-11-10 | |
| 2025-06-30 | 63.32K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 81.05K shares 10-Q · filed 2025-08-11 | 162.94K shares derived: sum of 3 quarters · filed 2025-08-11 | 228.70K shares derived: sum of 4 quarters · filed 2025-08-11 | |
| 2025-03-31 | 17.72K shares 10-Q · filed 2025-05-12 | 99.62K shares derived: sum of 2 quarters · filed 2025-05-12 | 165.38K shares derived: sum of 3 quarters · filed 2025-05-12 | 195.56K shares derived: sum of 4 quarters · filed 2025-05-12 | |
| 2024-12-31 | 81.89K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 147.66K shares derived: sum of 2 quarters · filed 2025-03-03 | 177.84K shares derived: sum of 3 quarters · filed 2025-03-03 | 186.34K shares 10-K · filed 2025-03-03 | |
| 2024-09-30 | 65.76K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 95.95K shares derived: sum of 2 quarters · filed 2024-11-12 | 104.45K shares 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | 30.18K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | 38.68K shares 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | 8.50K shares 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | 209.65K shares 10-K · filed 2024-02-29 | 86.25K shares 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |